These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38888709)

  • 1. Challenges associated with managing treatment complications in an older patient with cardiac amyloidosis.
    An SY; Yang Y
    Egypt Heart J; 2024 Jun; 76(1):75. PubMed ID: 38888709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.
    González-López E; Gallego-Delgado M; Guzzo-Merello G; de Haro-Del Moral FJ; Cobo-Marcos M; Robles C; Bornstein B; Salas C; Lara-Pezzi E; Alonso-Pulpon L; Garcia-Pavia P
    Eur Heart J; 2015 Oct; 36(38):2585-94. PubMed ID: 26224076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The quintessential form of diastolic heart failure in older adults: Wild type transthyretin cardiac amyloidosis.
    Driggin E; Maurer MS
    Clin Cardiol; 2020 Feb; 43(2):171-178. PubMed ID: 31825134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study.
    Aimo A; Vergaro G; Castiglione V; Fabiani I; Barison A; Gentile F; Ferrari Chen YF; Giorgetti A; Genovesi D; Buda G; Franzini M; Piepoli M; Moscardini S; Rapezzi C; Fontana M; Passino C; Emdin M
    Eur J Prev Cardiol; 2024 Aug; 31(11):1410-1417. PubMed ID: 38456769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determining patterns of vascular function and structure in wild-type transthyretin cardiac amyloidosis. A comparative study.
    Stamatelopoulos K; Delialis D; Georgiopoulos G; Tselegkidi MI; Theodorakakou F; Dialoupi I; Bambatsias D; Petropoulos I; Vergaro G; Ikonomidis I; Tzortzis S; Briasoulis A; Kanakakis J; Trougakos I; Dimopoulos MA; Kastritis E
    Int J Cardiol; 2022 Sep; 363():102-110. PubMed ID: 35716935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), previously known as senile cardiac amyloidosis: clinical presentation, diagnosis, management and emerging therapies.
    Halatchev IG; Zheng J; Ou J
    J Thorac Dis; 2018 Mar; 10(3):2034-2045. PubMed ID: 29707360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent Heart Failure Despite Medical Therapy Leading to a Diagnosis of Cardiac Amyloidosis.
    Maraj D; Ramanan S; Patel PM; Memon M; Hawes E
    Cureus; 2023 Aug; 15(8):e43547. PubMed ID: 37719596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience.
    Mints YY; Doros G; Berk JL; Connors LH; Ruberg FL
    ESC Heart Fail; 2018 Oct; 5(5):772-779. PubMed ID: 29916559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis.
    van den Berg MP; Mulder BA; Klaassen SHC; Maass AH; van Veldhuisen DJ; van der Meer P; Nienhuis HLA; Hazenberg BPC; Rienstra M
    Eur Heart J; 2019 Apr; 40(16):1287-1293. PubMed ID: 30753432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced trans-mitral A-wave velocity predicts the presence of wild-type transthyretin amyloidosis in elderly patients with left ventricular hypertrophy.
    Yamamura S; Izumiya Y; Ishida T; Onoue Y; Kimura Y; Hanatani S; Araki S; Fujisue K; Sueta D; Kanazawa H; Takashio S; Usuku H; Sugamura K; Sakamoto K; Yamamoto E; Yamamuro M; Yasuda H; Kojima S; Kaikita K; Hokimoto S; Ogawa H; Tsujita K
    Heart Vessels; 2017 Jun; 32(6):708-713. PubMed ID: 27882404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuromuscular manifestations of wild type transthyretin amyloidosis: a review and single center's experience.
    Živković SA; Lacomis D; Soman P
    Front Cardiovasc Med; 2024; 11():1345608. PubMed ID: 38410247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis.
    Kleefeld F; Scherret E; Knebel F; Messroghli D; Heidecker B; Wetz C; Schatka I; Barzen G; Tschöpe C; Amthauer H; Hahn K
    Amyloid; 2022 Jun; 29(2):92-101. PubMed ID: 34994254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey.
    Nativi-Nicolau J; Siu A; Dispenzieri A; Maurer MS; Rapezzi C; Kristen AV; Garcia-Pavia P; LoRusso S; Waddington-Cruz M; Lairez O; Witteles R; Chapman D; Amass L; Grogan M;
    JACC CardioOncol; 2021 Oct; 3(4):537-546. PubMed ID: 34729526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Senile systemic amyloidosis: clinical features at presentation and outcome.
    Pinney JH; Whelan CJ; Petrie A; Dungu J; Banypersad SM; Sattianayagam P; Wechalekar A; Gibbs SD; Venner CP; Wassef N; McCarthy CA; Gilbertson JA; Rowczenio D; Hawkins PN; Gillmore JD; Lachmann HJ
    J Am Heart Assoc; 2013 Apr; 2(2):e000098. PubMed ID: 23608605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated diagnostic approach to wild-type transthyretin cardiac amyloidosis with the use of high-sensitivity cardiac troponin T measurement and
    Ochi Y; Kubo T; Nakashima Y; Baba Y; Hirota T; Yamasaki N; Yamashita T; Ueda M; Ando Y; Kitaoka H
    J Cardiol; 2020 Jan; 75(1):12-19. PubMed ID: 31324572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of electron microscopy in the diagnosis of wild-type transthyretin cardiac amyloidosis.
    Sunayama I; Yoshimura T; Sonoura T; Nakamura Y; Morishita Y; Sekihara T; Ishimi M; Yamato M; Hoshida Y; Yasuoka Y
    J Cardiol Cases; 2021 Apr; 23(4):166-169. PubMed ID: 33841594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of wild-type transthyretin cardiac amyloidosis in patients with carpal tunnel syndrome surgery (CACTuS).
    Ladefoged B; Clemmensen T; Dybro A; Hartig-Andreasen C; Kirkeby L; Gormsen LC; Bomholt P; Gillmore J; Poulsen SH
    ESC Heart Fail; 2023 Feb; 10(1):234-244. PubMed ID: 36193570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transthyretin amyloid cardiomyopathy among patients with heart failure and preserved ejection fraction: the AMY score.
    Gioia G; Schrutka L; Jozwiak-Nozdrzykowska J; Kresoja KP; Gunold H; Klingel K; Thiele H; Bonderman D; Lurz P; Rommel KP
    ESC Heart Fail; 2024 Aug; 11(4):2172-2181. PubMed ID: 38613409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS).
    Campbell CM; LoRusso S; Dispenzieri A; Kristen AV; Maurer MS; Rapezzi C; Lairez O; Drachman B; Garcia-Pavia P; Grogan M; Chapman D; Amass L;
    Cardiol Ther; 2022 Sep; 11(3):393-405. PubMed ID: 35583798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types.
    Rapezzi C; Merlini G; Quarta CC; Riva L; Longhi S; Leone O; Salvi F; Ciliberti P; Pastorelli F; Biagini E; Coccolo F; Cooke RM; Bacchi-Reggiani L; Sangiorgi D; Ferlini A; Cavo M; Zamagni E; Fonte ML; Palladini G; Salinaro F; Musca F; Obici L; Branzi A; Perlini S
    Circulation; 2009 Sep; 120(13):1203-12. PubMed ID: 19752327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.